- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01842997
Safety of H1N1 Influenza Vaccination in Pregnant Women
April 25, 2013 updated by: fubaoma, Jiangsu Province Centers for Disease Control and Prevention
A Stratified and Controlled Clinical Trial With Split-virion, Non-adjuvanted Influenza A/H1N1 Vaccines in Healthy Pregnant Women
Since October 2009, H1N1 influenza vaccine has developed and approved of immunization in population in China.
However, there was little epidemiological evidence of safety when vaccinated in healthy pregnant women.
The main objective of this study is to assess the safety of split-virion inactivated H1N1 vaccine without adjuvant when administered in healthy pregnant women.
It is a stratified and controlled clinical trial in healthy pregnant women.
And participants were included up to 226 healthy pregnant women aged 18 -35 years old who have no history of novel influenza H1N1 infection or novel influenza H1N1 vaccination.
The pregnancy week ranged from 5 weeks to 32 weeks.
Subjects were divided into 2 groups: vaccinated group(122) and unvaccinated group(104).
Subjects in the vaccinated group were administered one dose of 15μg H1N1 vaccine.
Subjects in the unvaccinated group received no vaccine as controls.
Safety will be measured by assessment of pregnancy outcomes.
And observation time for pregnancy outcomes was lasting for 28 days postpartum since vaccinated; and protective effect was observed for six months.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
122
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Jiangsu
-
Xiangshui, Jiangsu, China, 224600
- Xiangshui Center for Disease Control and Prevention
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 35 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Healthy pregnant women
- Be able to show legal identity card for the sake of recruitment
- Be able to understand and sign the informed consent
Exclusion Criteria:
- Cases, cured cases and close contact of influenza A (H1N1) virus
- Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine, such as egg, egg protein, etc
- Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain
- Autoimmune disease or immunodeficiency
- Asthma that is unstable or required emergent care, hospitalization or intubation during the past two years or that required the use of oral or intravenous corticosteroids
- Diabetes mellitus (type I or II), with the exception of gestational diabetes
- History of thyroidectomy or thyroid disease that required medication within the past 12 months
- Serious angioedema episodes within the previous 3 years or requiring medication in the previous two years
- Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws
- Any history of immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis)
- History of any blood products or seasonal influenza vaccine administration within 3 months before the dosing
- Administration of any other investigational research agents within 30 days before the dosing
- Administration of any live attenuated vaccine within 30 days before the dosing
- Administration of subunit or inactivated vaccines, e.g., pneumococcal vaccine, or allergy treatment with antigen injections, within 14 days before the dosing
- Axillary temperature > 37.0 centigrade at the time of dosing
- Psychiatric condition that precludes compliance with the protocol
- Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: split-virion, non-adjuvanted H1N1 vaccine of 15 μg
split-virion, non-adjuvanted H1N1 vaccine of 15 μg made by Shanghai Institute of Biological Products lot number: 200909008
|
122 participants (19 at 5-9 weeks pregnant,36 at 10-19 weeks pregnant,13 at 20-29 weeks pregnant,54 at more than 30 weeks pregnant) received split-virion, non-adjuvanted H1N1 vaccine of 15 μg.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Pregnancy Outcomes
Time Frame: 0-28 days postpartum
|
include the following indicators: incidence of spontaneous abortion, incidence of induced abortion,incidence of Preterm, incidence of post-term pregnancy, proportion of underweight-Babies
|
0-28 days postpartum
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
incidence of influenza-like illness
Time Frame: 0-6months
|
0-6months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Fubao Ma, Jiangsu Province Centers for Disease Control and Prevention
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2009
Primary Completion (Actual)
December 1, 2010
Study Completion (Actual)
December 1, 2010
Study Registration Dates
First Submitted
April 24, 2013
First Submitted That Met QC Criteria
April 25, 2013
First Posted (Estimate)
April 30, 2013
Study Record Updates
Last Update Posted (Estimate)
April 30, 2013
Last Update Submitted That Met QC Criteria
April 25, 2013
Last Verified
April 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- JSEPI-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Virus Diseases
-
Institute of Tropical Medicine, BelgiumCompletedTransmission | Zika Virus | Zika Virus Disease | Virus SheddingBelgium
-
TakedaCompletedFlavivirus Infections | Healthy Participants | Virus, Zika | Zika Virus DiseaseUnited States, Puerto Rico
-
U.S. Army Medical Research and Development CommandActive, not recruiting
-
Emergent BioSolutionsCompletedZika Virus Infection | Zika Virus DiseaseCanada
-
National Institute of Allergy and Infectious Diseases...CompletedHealthy | Epstein Barr Virus InfectionUnited States
-
U.S. Army Medical Research and Development CommandCompleted
-
Merck Sharp & Dohme LLCCompletedVaricella Virus Infection
-
Valneva Austria GmbHEmergent BioSolutionsCompletedZika Virus Infection | Zika VirusUnited States
-
Sun Yat-sen UniversityWuzhou Red Cross Hospital; Zhongshan People's Hospital, Guangdong, ChinaRecruiting
-
RTI InternationalEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsUnknown
Clinical Trials on split-virion, non-adjuvanted H1N1 vaccine of 15 μg
-
Jiangsu Province Centers for Disease Control and...Hualan Biological Bacterin Co. Ltd.CompletedVirus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases | Influenza | Orthomyxoviridae InfectionsChina
-
Shanghai Institute Of Biological ProductsCompleted
-
Shanghai Institute Of Biological ProductsCompleted
-
Shanghai Public Health Clinical CenterBeijing Ditan Hospital; National Institute for the Control of Pharmaceutical...UnknownVirus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases | Influenza | Orthomyxoviridae InfectionsChina
-
Chinese Academy of SciencesJiangsu Province Centers for Disease Control and Prevention; Hualan Biological...Unknown
-
Green Cross CorporationCompleted
-
Sanofi Pasteur, a Sanofi CompanyCompletedInfluenza | Swine-origin A/H1N1 InfluenzaFinland
-
Sanofi Pasteur, a Sanofi CompanyCompletedInfluenza | Swine-origin A/H1N1 InfluenzaFinland
-
Sinovac Biotech Co., LtdCompleted